Literature DB >> 10086390

The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation.

D Georgakopoulos1, M E Christe, M Giewat, C M Seidman, J G Seidman, D A Kass.   

Abstract

Familial hypertrophic cardiomyopathy (FHC) is a genetic disorder resulting from mutations in genes encoding sarcomeric proteins. This typically induces hyperdynamic ejection, impaired relaxation, delayed early filling, myocyte disarray and fibrosis, and increased chamber end-systolic stiffness. To better understand the disease pathogenesis, early (primary) abnormalities must be distinguished from evolving responses to the genetic defect. We did in vivo analysis using a mouse model of FHC with an Arg403Gln alpha-cardiac myosin heavy chain missense mutation, and used newly developed methods for assessing in situ pressure-volume relations. Hearts of young mutant mice (6 weeks old), which show no chamber morphologic or gross histologic abnormalities, had altered contraction kinetics, with considerably delayed pressure relaxation and chamber filling, yet accelerated systolic pressure rise. Older mutant mice (20 weeks old), which develop fiber disarray and fibrosis, had diastolic and systolic kinetic changes similar to if not slightly less than those of younger mice. However, the hearts of older mutant mice also showed hyperdynamic contraction, with increased end-systolic chamber stiffness, outflow tract pressure gradients and a lower cardiac index due to reduced chamber filling; all 'hallmarks' of human disease. These data provide new insights into the temporal evolution of FHC. Such data may help direct new therapeutic strategies to diminish disease progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086390     DOI: 10.1038/6549

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  51 in total

Review 1.  Molecular genetics of cardiomyopathies.

Authors:  G Shah; R Roberts
Journal:  J Nucl Cardiol       Date:  2000 Mar-Apr       Impact factor: 5.952

2.  beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility.

Authors:  P Varghese; R W Harrison; R A Lofthouse; D Georgakopoulos; D E Berkowitz; J M Hare
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

3.  Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.

Authors:  Tetsuo Konno; Dan Chen; Libin Wang; Hiroko Wakimoto; Polakit Teekakirikul; Matthew Nayor; Masataka Kawana; Seda Eminaga; Joshua M Gorham; Kumar Pandya; Oliver Smithies; Francisco J Naya; Eric N Olson; J G Seidman; Christine E Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

Review 4.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

Review 5.  Hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho
Journal:  Heart Fail Clin       Date:  2010-04       Impact factor: 3.179

Review 6.  Role of animal models in HCM research.

Authors:  Rhian Shephard; Christopher Semsarian
Journal:  J Cardiovasc Transl Res       Date:  2009-08-07       Impact factor: 4.132

Review 7.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

8.  Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.

Authors:  Sarah A Clay; Timothy L Domeier; Laurin M Hanft; Kerry S McDonald; Maike Krenz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

9.  Impaired up-regulation of CD25 on CD4+ T cells in IFN-gamma knockout mice is associated with progression of myocarditis to heart failure.

Authors:  Marina Afanasyeva; Dimitrios Georgakopoulos; Diego F Belardi; Djahida Bedja; Delisa Fairweather; Yan Wang; Ziya Kaya; Kathleen L Gabrielson; E Rene Rodriguez; Patrizio Caturegli; David A Kass; Noel R Rose
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

10.  Dysfunction of dysferlin-deficient hearts.

Authors:  Katrin Wenzel; Christian Geier; Fatimunnisa Qadri; Norbert Hubner; Herbert Schulz; Bettina Erdmann; Volkmar Gross; David Bauer; Ralf Dechend; Rainer Dietz; Karl Josef Osterziel; Simone Spuler; Cemil Ozcelik
Journal:  J Mol Med (Berl)       Date:  2007-09-09       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.